Uploaded February 2021 | Updated September 2026, 1 week ago
To read more about the discovery: insilico.com/blog/pcc
Dr. Yuri Nikolsky
CEO at MiLaboratories
CEO Sybille BioSciences
Co-founder of GeneGo (acquired by Thomson Reuters)
Former VP of Life Sciences, Thomson Reuters
Developer of MetaCore, MetaBase, and other tools for target discovery
H-index = 48
To read more about the discovery: insilico.com/blog/pcc
Dr. Yuri Nikolsky
CEO at MiLaboratories
CEO Sybille BioSciences
Co-founder of GeneGo (acquired by Thomson Reuters)
Former VP of Life Sciences, Thomson Reuters
Developer of MetaCore, MetaBase, and other tools for target discovery
H-index = 48
![[Nature Communications] Oral ENPP1 Inhibitor as Next Generation STING Modulator for Solid Tumors](https://i.ytimg.com/vi/R9wa1NeqVZg/mqdefault.jpg "[Nature Communications] Oral ENPP1 Inhibitor as Next Generation STING Modulator for Solid Tumors
Cold tumors are cancers with little to no immune cell infiltration. They lack the ability to activate the immune system, leaving patients with few options. Recently, Insilico Medicine announced breakthrough findings in immune oncology therapy targeting ENPP1, published in Nature Communications, a leading peer reviewed journal.")
